DRR168560
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- sex
- Female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.630
- G2M_CHECKPOINT+0.620
- INTERFERON_ALPHA_RESPONSE+0.610
- MYC_TARGETS_V2+0.600
- MYC_TARGETS_V1+0.570
- INTERFERON_GAMMA_RESPONSE+0.510
- OXIDATIVE_PHOSPHORYLATION+0.460
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.430
- MTORC1_SIGNALING+0.410
- DNA_REPAIR+0.370
Top 10 suppressed
- BILE_ACID_METABOLISM-0.390
- TGF_BETA_SIGNALING-0.320
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.310
- ESTROGEN_RESPONSE_EARLY-0.260
- UV_RESPONSE_DN-0.180
- NOTCH_SIGNALING-0.160
- PANCREAS_BETA_CELLS-0.160
- TNFA_SIGNALING_VIA_NFKB-0.150
- KRAS_SIGNALING_UP-0.130
- HYPOXIA-0.120
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-PQ-A6FI-01A-11R-A31N-07 | — | — | 0.874 |
| 2 | TCGA-HD-7832-01A-11R-2132-07 | — | — | 0.871 |
| 3 | SRR8518360 | — | E | 0.850 |
| 4 | E0173AAB-678A-46E0-B701-C79A6BE9B9D8 | — | — | 0.844 |
| 5 | TCGA-18-3416-01A-01R-0980-07 | — | cohortSQ2 | 0.838 |
| 6 | TCGA-39-5016-01A-01R-1443-07 | — | cohortSQ2 | 0.832 |
| 7 | TCGA-T3-A92N-01A-11R-A39I-07 | — | — | 0.829 |
| 8 | e8381a92.5379.4ece.8414.230d0f0026e1 | — | cohortA1 | 0.824 |
| 9 | TCGA-66-2794-01A-01R-1201-07 | — | cohortSQ2 | 0.821 |
| 10 | DRR168607 | — | — | 0.821 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 29 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.630 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.620 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.610 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.600 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.570 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.510 | Idelalisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.460 | Remibrutinib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.430 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.410 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.370 | Idelalisib | — uncovered |
| MITOTIC_SPINDLE | 0.300 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.290 | Idelalisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.270 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.220 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.220 | Inavolisib | — uncovered |
| COMPLEMENT | 0.210 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.200 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.200 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.190 | Remibrutinib | — uncovered |
| GLYCOLYSIS | 0.170 | Inavolisib | — uncovered |